Further analysis showed that among the 34 gene mutations, the incidence of ASXL1 and TET2 gene mutations was significantly higher in the IO MDS group (6/10, 7/10) than that in the NIO MDS group (1/11, 2/11) (p < 0.05) (Table 3), which suggested that the BMMNC from IO MDS patients might be more prone to genetic abnormalities and damaged by iron overload. This evidence concerns the gene TET2 and myelodysplastic syndrome.